Sanofi: restructures deal with Regeneron Pharmaceuticals
(CercleFinance.com) - Sanofi and Regeneron Pharmaceuticals have announced that they have restructured their global Immuno-oncology Discovery and Development Agreement for new immune-oncology cancer treatments, an agreement that dates back to 2015 and which was due to end in mid-2020.
This revision provides for ongoing collaborative development of two clinical stage bispecific antibody programs. This provides Sanofi increased flexibility to advance its early-stage immuno-oncology pipeline independently.
Sanofi will pay Regeneron 462 million dollars, representing the balance of payments due in immune-oncology, up to 120 million dollars in development costs for the two selected clinical-stage bispecific antibodies, plus the termination fee for the other programs under the original immuno-oncology agreement.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
This revision provides for ongoing collaborative development of two clinical stage bispecific antibody programs. This provides Sanofi increased flexibility to advance its early-stage immuno-oncology pipeline independently.
Sanofi will pay Regeneron 462 million dollars, representing the balance of payments due in immune-oncology, up to 120 million dollars in development costs for the two selected clinical-stage bispecific antibodies, plus the termination fee for the other programs under the original immuno-oncology agreement.
Copyright (c) 2019 CercleFinance.com. All rights reserved.